BACKGROUND: This report analyzes the adherence to radiation therapy protocol guidelines in contemporary Radiation Therapy Oncology Group (RTOG) gastrointestinal trials. We aim to provide insight into current standards and compliance of radiation therapy field design and administration. METHODS: From 1994 to 2006, the Gastrointestinal Cancer Committee of the RTOG initiated and completed 15 phase I-III clinical trials utilizing radiation therapy in the multimodality treatment of gastrointestinal cancers. In each protocol, details for planning and executing radiation therapy were outlined and each protocol contained scoring criteria for these components of radiation therapy, characterized according to per-protocol, variation acceptable and deviation unacceptable. Review of treatment planning and implementation was performed in all studies following therapy completion. RESULTS: Radiation therapy planning and implementation was reviewed in 2309 of 2312 (99.9%) patients. The mean rate of compliance over all for the 15 protocols was 65% (total of the 2309 analyzed patients). The mean variation acceptable rate was 21% whereas the mean deviation unacceptable rate was 5%. The mean "other" rate (no RT given or incomplete RT due to death, progression or refusal) was 8%. Two of the 15 trials (13%) had deviation unacceptable rates >10%. In four studies incorporating pre-treatment review of radiation therapy planning and treatment, compliance with protocol therapy was enhanced. CONCLUSIONS: The fidelity of radiation planning and execution detailed in protocol to actual therapy is heterogeneous, with a mean per-protocol rate of 65%. As clinical trials evolve, available technology should permit efficient pre-treatment review processes, thus facilitating compliance to protocol therapy. These analyses should also permit prospective analysis of outcome measures by compliance to therapy.
BACKGROUND: This report analyzes the adherence to radiation therapy protocol guidelines in contemporary Radiation Therapy Oncology Group (RTOG) gastrointestinal trials. We aim to provide insight into current standards and compliance of radiation therapy field design and administration. METHODS: From 1994 to 2006, the Gastrointestinal Cancer Committee of the RTOG initiated and completed 15 phase I-III clinical trials utilizing radiation therapy in the multimodality treatment of gastrointestinal cancers. In each protocol, details for planning and executing radiation therapy were outlined and each protocol contained scoring criteria for these components of radiation therapy, characterized according to per-protocol, variation acceptable and deviation unacceptable. Review of treatment planning and implementation was performed in all studies following therapy completion. RESULTS: Radiation therapy planning and implementation was reviewed in 2309 of 2312 (99.9%) patients. The mean rate of compliance over all for the 15 protocols was 65% (total of the 2309 analyzed patients). The mean variation acceptable rate was 21% whereas the mean deviation unacceptable rate was 5%. The mean "other" rate (no RT given or incomplete RT due to death, progression or refusal) was 8%. Two of the 15 trials (13%) had deviation unacceptable rates >10%. In four studies incorporating pre-treatment review of radiation therapy planning and treatment, compliance with protocol therapy was enhanced. CONCLUSIONS: The fidelity of radiation planning and execution detailed in protocol to actual therapy is heterogeneous, with a mean per-protocol rate of 65%. As clinical trials evolve, available technology should permit efficient pre-treatment review processes, thus facilitating compliance to protocol therapy. These analyses should also permit prospective analysis of outcome measures by compliance to therapy.
Authors: Alysa Fairchild; Edwin Aird; Paul A Fenton; Vincent Gregoire; Akos Gulyban; Denis Lacombe; Oscar Matzinger; Philip Poortmans; Pascal Ruyskart; Damien C Weber; Coen W Hurkmans Journal: Radiother Oncol Date: 2012-05-23 Impact factor: 6.280
Authors: Berthe M P Aleman; Théodore Girinsky; Richard W M van der Maazen; Simon Strijk; Paul Meijnders; Roberto Bortolus; Manouk J J Olofsen-van Acht; Marnix L M Lybeert; Yolande Lievens; Houchingue Eghbali; Evert M Noordijk; Radka Tomsic; Jacobus H Meerwaldt; Philip M P Poortmans; Wilma G J M Smit; Antonella Pinna; Michel Henry-Amar; John M M Raemaekers Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-02 Impact factor: 7.038
Authors: Elena Musat; Philip Poortmans; Walter Van den Bogaert; Henk Struikmans; Alain Fourquet; Harry Bartelink; Carine Kirkove; Volker Budach; Marianne Pierart; Laurence Collette Journal: Eur J Cancer Date: 2007-01-19 Impact factor: 9.162
Authors: Anke M van Mourik; Paula H M Elkhuizen; Danny Minkema; Joop C Duppen; Corine van Vliet-Vroegindeweij Journal: Radiother Oncol Date: 2010-03-02 Impact factor: 6.280
Authors: Vassilis E Kouloulias; Jean-Francois Bosset; Geertjan van Tienhoven; Bernard J Davis; Marianne Pierart; Philip Poortmans Journal: Eur J Cancer Date: 2002-09 Impact factor: 9.162
Authors: Christopher H Crane; Kathryn Winter; William F Regine; Howard Safran; Tyvin A Rich; Walter Curran; Robert A Wolff; Christopher G Willett Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Oscar Matzinger; Erich Gerber; Zvi Bernstein; Philippe Maingon; Karin Haustermans; Jean François Bosset; Akos Gulyban; Philip Poortmans; Laurence Collette; Abraham Kuten Journal: Radiother Oncol Date: 2009-04-15 Impact factor: 6.280
Authors: Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett Journal: JAMA Date: 2008-04-23 Impact factor: 56.272
Authors: Tyvin A Rich; Kathryn Winter; Howard Safran; John P Hoffman; Beth Erickson; Pramila R Anne; Robert J Myerson; Vivian Jm Cline-Burkhardt; Kimberly Perez; Christopher Willett Journal: Onco Targets Ther Date: 2012-08-23 Impact factor: 4.147
Authors: Kelsey L Corrigan; Stephen Kry; Rebecca M Howell; Ramez Kouzy; Joseph Abi Jaoude; Roshal R Patel; Anuja Jhingran; Cullen Taniguchi; Albert C Koong; Mary Fran McAleer; Paige Nitsch; Claus Rödel; Emmanouil Fokas; Bruce D Minsky; Prajnan Das; C David Fuller; Ethan B Ludmir Journal: Radiother Oncol Date: 2021-11-25 Impact factor: 6.280
Authors: Christos Melidis; Walter R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Satoshi Ishikura; David Followill; James Galvin; Ying Xiao; Martin A Ebert; Tomas Kron; Catharine H Clark; Elizabeth A Miles; Edwin G A Aird; Damien C Weber; Kenneth Ulin; Dirk Verellen; Coen W Hurkmans Journal: Radiother Oncol Date: 2014-05-08 Impact factor: 6.280
Authors: Eva Versteijne; Eelco Lens; Astrid van der Horst; Arjan Bel; Jorrit Visser; Cornelis J A Punt; Mustafa Suker; Casper H J van Eijck; Geertjan van Tienhoven Journal: Strahlenther Onkol Date: 2017-06-12 Impact factor: 3.621
Authors: Luciana Caravatta; Gabriella Macchia; Gian Carlo Mattiucci; Aldo Sainato; Nunzia L V Cernusco; Giovanna Mantello; Monica Di Tommaso; Marianna Trignani; Antonino De Paoli; Gianni Boz; Maria L Friso; Vincenzo Fusco; Marta Di Nicola; Alessio G Morganti; Domenico Genovesi Journal: Radiat Oncol Date: 2014-09-08 Impact factor: 3.481
Authors: Daniel L P Holyoake; Elizabeth Ward; Derek Grose; David McIntosh; David Sebag-Montefiore; Ganesh Radhakrishna; Neel Patel; Michael Silva; Somnath Mukherjee; Victoria Y Strauss; Lang'o Odondi; Emmanouil Fokas; Alan Melcher; Maria A Hawkins Journal: BMC Cancer Date: 2016-09-13 Impact factor: 4.430